In Brief This Week: Qiagen, Mayo Clinic; Illumina; FDA, DNA Genotek; Agilent; NeoGenomics; Epigenomics; More | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen this week announced a partnership and licensing options with Mayo Clinic. The deal covers the use of the IDH1 and IDH2 biomarkers for diagnosing cholangiocarcinoma and guiding treatment for the disease, a rare form of cancer that affects between 2,000 and 3,000 patients each year in the US. The partners will collaborate on developing new IDH1/2 products for cholangiocarcinoma. Financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.